Rita F. Redberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rita F. Redberg has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
Sanket S. Dhruva
Section of Cardiology, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California
13 shared publications- Sanket S. Dhruva
University of California, San Francisco School of Medicine, San Francisco, CA, USA
9 shared publications Mitchell H. Katz
NYC Health + Hospitals, New York, New York
8 shared publications- Lisa Bero
Center for Bioethics and Humanities, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
5 shared publications - Aaron Seth Kesselheim
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
3 shared publications Grace A. Lin
Division of General Internal Medicine, University of California, San Francisco, USA
3 shared publications
Latest Publications
- Open Access
Evaluation of the accuracy, completeness, and compliance of current summary reporting of adverse events to the Food and Drug Administration using the manufacturer and user facility device experience (MAUDE) database: cross sectional study
Objectives: To evaluate the accuracy and completeness of adverse event summary reports for medical devices and compliance of the reports with the Food and Drug Administration (FDA) requirements. Design: Cross sectional study. Setting: The FDA manufacturer and user facility device experience (MAUDE) database. Participants: All adverse event summary reports filed in MAUDE from July 2019 to June 2025. Main outcome measures: Identification of device problem codes, appropriate identification as summary reports in the submission form, concordance between the number of events data field and the report narrative, and compliance with FDA reporting deadlines. Results: 6308 summary reports were submitted to MAUDE containing 159 503 adverse events. Use of summary reports increased from 808 to 1757 between 2020 and 2024, a factor of 1.21 per year (P<0.001). Most (91%) adverse events in summary reports were for class 3 high risk devices. Summary reports lacked descriptions of potential device related problems: 57% of reports denoted an “adverse event without identified device or use problem” and 38% of reports selected “insufficient information” in the device problem code data field. Manufacturers incorrectly checked “N” (no) in the summary report (Y/N, reporting yes/no) field for 694 summary reports (11%) and erroneously listed “n=1” under the number of events field for 423 summary reports (7%), causing an undercount of 11 902 adverse events. The majority (55%) of summary reports failed to comply with the FDA reporting deadline of 30 days after the manufacturer became aware of the adverse event. Conclusions: Adverse event summary reports in MAUDE are frequently incomplete, inaccurate, and delayed. Improvements are needed to ensure timely identification of device safety signals and uphold FDA transparency standards.
Open AccessEvaluation of the accuracy, completeness, and compliance of current summary reporting of adverse events to the Food and Drug Administration using the manufacturer and user facility device experience (MAUDE) database: cross sectional study
Objectives: To evaluate the accuracy and completeness of adverse event summary reports for medical devices and compliance of the reports with the Food and Drug Administration (FDA) requirements. Design: Cross sectional study. Setting: The FDA manufacturer and user facility device experience (MAUDE) database. Participants: All adverse event summary reports filed in MAUDE from July 2019 to June 2025. Main outcome measures: Identification of device problem codes, appropriate identification as summary reports in the submission form, concordance between the number of events data field and the report narrative, and compliance with FDA reporting deadlines. Results: 6308 summary reports were submitted to MAUDE containing 159 503 adverse events. Use of summary reports increased from 808 to 1757 between 2020 and 2024, a factor of 1.21 per year (P<0.001). Most (91%) adverse events in summary reports were for class 3 high risk devices. Summary reports lacked descriptions of potential device related problems: 57% of reports denoted an “adverse event without identified device or use problem” and 38% of reports selected “insufficient information” in the device problem code data field. Manufacturers incorrectly checked “N” (no) in the summary report (Y/N, reporting yes/no) field for 694 summary reports (11%) and erroneously listed “n=1” under the number of events field for 423 summary reports (7%), causing an undercount of 11 902 adverse events. The majority (55%) of summary reports failed to comply with the FDA reporting deadline of 30 days after the manufacturer became aware of the adverse event. Conclusions: Adverse event summary reports in MAUDE are frequently incomplete, inaccurate, and delayed. Improvements are needed to ensure timely identification of device safety signals and uphold FDA transparency standards.
- Open Access
INSPECT-SR tool for assessing trustworthiness of randomised controlled trials
The integrity of evidence synthesis is threatened by problematic randomised controlled trials, where there are serious concerns about the trustworthiness of the data or findings. Such concerns could be due to research misconduct, including fraud, or due to honest critical errors. If these trials are not detected, they may be inadvertently included in systematic reviews and guidelines, potentially distorting their results. To resolve this problem, the INSPECT-SR (Investigating Problematic Clinical Trials in Systematic Reviews) tool has been developed to assess the trustworthiness of randomised controlled trials. This tool will help researchers to identify and exclude problematic trials from systematic reviews. This article describes the development of INSPECT-SR and presents the tool and an associated guidance document.
Open AccessINSPECT-SR tool for assessing trustworthiness of randomised controlled trials
The integrity of evidence synthesis is threatened by problematic randomised controlled trials, where there are serious concerns about the trustworthiness of the data or findings. Such concerns could be due to research misconduct, including fraud, or due to honest critical errors. If these trials are not detected, they may be inadvertently included in systematic reviews and guidelines, potentially distorting their results. To resolve this problem, the INSPECT-SR (Investigating Problematic Clinical Trials in Systematic Reviews) tool has been developed to assess the trustworthiness of randomised controlled trials. This tool will help researchers to identify and exclude problematic trials from systematic reviews. This article describes the development of INSPECT-SR and presents the tool and an associated guidance document.
- Open Access
- 7 September 2026
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 54 (3) , 417-419
Industry Exposure in Medical Training: The Case for a Conflict-Free Learning Environment
Conflicts of interest (COI) between physicians and for-profit companies have existed for centuries, but the last decade has dramatically increased their visibility through the Centers for Medicare and Medicaid Services’ Open Payments database. Despite growing documentation of COI in academic medical environments — where financial relationships are prevalent and industry payments to trainees exceed millions of dollars annually — formal COI policies and curriculum in US medical schools have stagnated or weakened since the last major wave of reform over a decade ago. The authors review the evidence linking industry interactions during medical training to favorable views of pharmaceutical marketing, greater propensity for continued industry engagement, and increased prescribing of promoted drugs and devices. The authors argue that medical schools and their governing bodies must implement and enforce meaningful COI policies, meeting at minimum the Association of American Medical Colleges’ existing recommendations. The authors further recommend that the Liaison Committee on Medical Education require adherence to these policies for annual accreditation, that research curricula address the influence of funding sources on study design, and that the Open Payments database be integrated into medical training as a transparency tool. Strengthening COI education and policy is essential to ensure that the next generation of physicians learns in environments where patient-centered, evidence-based medicine guides decision-making.
- 7 September 2026
- Published by Cambridge University Press (CUP) in Journal of Law, Medicine & Ethics
- Vol. 54 (3) , 417-419
Open AccessIndustry Exposure in Medical Training: The Case for a Conflict-Free Learning Environment
Conflicts of interest (COI) between physicians and for-profit companies have existed for centuries, but the last decade has dramatically increased their visibility through the Centers for Medicare and Medicaid Services’ Open Payments database. Despite growing documentation of COI in academic medical environments — where financial relationships are prevalent and industry payments to trainees exceed millions of dollars annually — formal COI policies and curriculum in US medical schools have stagnated or weakened since the last major wave of reform over a decade ago. The authors review the evidence linking industry interactions during medical training to favorable views of pharmaceutical marketing, greater propensity for continued industry engagement, and increased prescribing of promoted drugs and devices. The authors argue that medical schools and their governing bodies must implement and enforce meaningful COI policies, meeting at minimum the Association of American Medical Colleges’ existing recommendations. The authors further recommend that the Liaison Committee on Medical Education require adherence to these policies for annual accreditation, that research curricula address the influence of funding sources on study design, and that the Open Payments database be integrated into medical training as a transparency tool. Strengthening COI education and policy is essential to ensure that the next generation of physicians learns in environments where patient-centered, evidence-based medicine guides decision-making.
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (8) , e013375
Assessment of Patient-Centered Content on Left Ventricular Assist Devices on US Hospital Webpages
- 1 August 2026
- Published by Wolters Kluwer Health in Circulation: Population Health and Outcomes
- Vol. 19 (8) , e013375
Assessment of Patient-Centered Content on Left Ventricular Assist Devices on US Hospital Webpages
- Open Access
- 29 November 2025
- Published by Maad Rayan Publishing Company in International Journal of Health Policy and Management
- Vol. 14
From Registry to Reality: Opportunities to Enhance Post-market Surveillance of High-Risk Medical Devices Comment on "Quality and Utility of European Cardiovascular and Orthopaedic Registries for the Regulatory Evaluation of Medical Device Safety and Performance Across the Implant Lifecycle: A Systematic Review"
Both the US Food and Drug Administration (FDA) and European Medical Device Regulation maintain the authority to require post-market surveillance for novel, high-risk medical devices. Yet, the current post-market surveillance system has several limitations. In their systematic review, Hoogervorst and colleagues highlight opportunities for improvement in the European medical device registries for the cardiovascular and orthopedic fields by standardised reporting of structural and methodological characteristics. Currently, there is heterogeneity in the governance, data collection, data reporting, and auditing of post-market surveillance registries, which limits their utility. Innovation in post-market surveillance mechanisms should include developing consensus around standardized safety outcomes by health condition, using artificial intelligence to identify patterns of harm in large or unstructured databases, continuing to invest in active surveillance networks to ensure the safety and effectiveness of high-risk medical devices, and educating physicians and care providers around adverse event reporting mechanisms. More resources and prioritization of post-market surveillance globally is needed to prioritize patient safety.
- 29 November 2025
- Published by Maad Rayan Publishing Company in International Journal of Health Policy and Management
- Vol. 14
Open AccessFrom Registry to Reality: Opportunities to Enhance Post-market Surveillance of High-Risk Medical Devices Comment on "Quality and Utility of European Cardiovascular and Orthopaedic Registries for the Regulatory Evaluation of Medical Device Safety and Performance Across the Implant Lifecycle: A Systematic Review"
Both the US Food and Drug Administration (FDA) and European Medical Device Regulation maintain the authority to require post-market surveillance for novel, high-risk medical devices. Yet, the current post-market surveillance system has several limitations. In their systematic review, Hoogervorst and colleagues highlight opportunities for improvement in the European medical device registries for the cardiovascular and orthopedic fields by standardised reporting of structural and methodological characteristics. Currently, there is heterogeneity in the governance, data collection, data reporting, and auditing of post-market surveillance registries, which limits their utility. Innovation in post-market surveillance mechanisms should include developing consensus around standardized safety outcomes by health condition, using artificial intelligence to identify patterns of harm in large or unstructured databases, continuing to invest in active surveillance networks to ensure the safety and effectiveness of high-risk medical devices, and educating physicians and care providers around adverse event reporting mechanisms. More resources and prioritization of post-market surveillance globally is needed to prioritize patient safety.
Rapid cardioversion for acute atrial fibrillation
Questions about the safety of vernakalant remain
- 1 November 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (11) , e011497
Insurer Coverage of Invasive Coronary Angiography and Percutaneous Coronary Intervention for Stable Coronary Artery Disease in the United States Compared With Guidelines and Landmark Trials
BACKGROUND: Invasive coronary angiography (ICA) and percutaneous coronary intervention (PCI) are common procedures for the diagnosis and treatment of coronary artery disease (CAD). These procedures are typically performed within the parameters of insurance coverage, but little is known about how insurance policies align with guidelines and landmark randomized clinical trials. METHODS: We developed 6 use cases (3 each for ICA and PCI) of clinical scenarios for stable CAD commonly encountered in clinical practice and compared policies of the largest US public and private payers (based on total revenue and number of beneficiaries) to the 2012 and 2023 professional society guidelines as well as the ORBITA (Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) and ISCHEMIA (Initial Invasive or Conservative Strategy for Stable Coronary Disease) trials. We classified policies as more restrictive, equal, or less restrictive than the guidelines and published randomized clinical trials by evaluating them on parameters of optimal medical therapy (OMT) and noninvasive imaging for ICA policies; and OMT, anatomic severity of CAD, and ability to proceed with PCI for PCI policies. We summarized findings with descriptive statistics. RESULTS: Among 33 payers, 18 (55%) ICA and 14 (42%) PCI policies were publicly available. When comparing requirements for OMT among symptomatic patients before ICA, 22% of policies were less restrictive, 75% were equivalent, and 3% were more restrictive than the 2012 and 2023 professional society guidelines. For the number of OMT medications among symptomatic patients before ICA, 44% were less restrictive and 56% were equivalent compared with the ORBITA trial. When comparing requirements for OMT for symptomatic patients before PCI, 21% of policies were less restrictive, 75% were equivalent, and 4% were more restrictive than the 2012 and 2023 guidelines. CONCLUSIONS: ICA and PCI coverage policies were only publicly available for approximately half of the largest US insurers, indicating need for greater transparency. When available, policies were variable in their alignment with clinical practice guidelines.
- 1 November 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (11) , e011497
Insurer Coverage of Invasive Coronary Angiography and Percutaneous Coronary Intervention for Stable Coronary Artery Disease in the United States Compared With Guidelines and Landmark Trials
BACKGROUND: Invasive coronary angiography (ICA) and percutaneous coronary intervention (PCI) are common procedures for the diagnosis and treatment of coronary artery disease (CAD). These procedures are typically performed within the parameters of insurance coverage, but little is known about how insurance policies align with guidelines and landmark randomized clinical trials. METHODS: We developed 6 use cases (3 each for ICA and PCI) of clinical scenarios for stable CAD commonly encountered in clinical practice and compared policies of the largest US public and private payers (based on total revenue and number of beneficiaries) to the 2012 and 2023 professional society guidelines as well as the ORBITA (Objective Randomized Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) and ISCHEMIA (Initial Invasive or Conservative Strategy for Stable Coronary Disease) trials. We classified policies as more restrictive, equal, or less restrictive than the guidelines and published randomized clinical trials by evaluating them on parameters of optimal medical therapy (OMT) and noninvasive imaging for ICA policies; and OMT, anatomic severity of CAD, and ability to proceed with PCI for PCI policies. We summarized findings with descriptive statistics. RESULTS: Among 33 payers, 18 (55%) ICA and 14 (42%) PCI policies were publicly available. When comparing requirements for OMT among symptomatic patients before ICA, 22% of policies were less restrictive, 75% were equivalent, and 3% were more restrictive than the 2012 and 2023 professional society guidelines. For the number of OMT medications among symptomatic patients before ICA, 44% were less restrictive and 56% were equivalent compared with the ORBITA trial. When comparing requirements for OMT for symptomatic patients before PCI, 21% of policies were less restrictive, 75% were equivalent, and 4% were more restrictive than the 2012 and 2023 guidelines. CONCLUSIONS: ICA and PCI coverage policies were only publicly available for approximately half of the largest US insurers, indicating need for greater transparency. When available, policies were variable in their alignment with clinical practice guidelines.
- Open Access
- 8 October 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58
Charting a path through high-risk medical device regulation: recommendations from the CORE-MD consortium
- 8 October 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 58
Open AccessCharting a path through high-risk medical device regulation: recommendations from the CORE-MD consortium
- Top Cited PapersOpen Access
Late adverse event reporting from medical device manufacturers to the US Food and Drug Administration: cross sectional study
Objective To describe the extent of late adverse event reporting by manufacturers to the US Food and Drug Administration’s (FDA) Manufacturer And User Facility Device Experience (MAUDE) database as well as the distribution of late reporting among manufacturers and associations with device characteristics. Design Cross sectional study. Setting The FDA MAUDE database, a central postmarket safety surveillance tool for US medical devices, from 1 September 2019 to 31 December 2022. Participants Medical device manufacturers that submitted initial adverse event reports to the FDA between 1 September 2019 and 31 December 2022. Main outcome measures Time in days between date manufacturer was notified of event and date of FDA receipt of adverse event reports, proportion of reports reported late (after the required 30 day window as required by FDA regulation), and distribution of late reporting among manufacturers and medical devices. Results 13 587 reports were of deaths, 1 552 268 of injuries, and 2 866 693 of malfunctions received by the FDA from 3028 unique manufacturers and 88 448 unique medical devices in the three and a half year period. Of 4 432 548 included reports, 71.0% (n=3 146 957) of adverse events were reported within 30 days (on time), 4.5% (n=197 606) were reported between 31 and 180 days (late), and 9.1% (n=402 891) were after 180 days (late). 15.5% of reports (n=685 094) had missing or invalid date data provided by the manufacturer. Three manufactures and 13 medical devices were attributed to 54.8% of late reports. Conclusions Nearly a third of manufacturer reports of medical device adverse events were not demonstrably submitted to the FDA within the regulatory deadline, with most late reports being submitted more than six months after manufacturer notification. Most late reports were submitted by a small number of manufacturers. Late adverse event reporting may prevent early detection of patient safety concerns.
Top Cited PapersOpen AccessLate adverse event reporting from medical device manufacturers to the US Food and Drug Administration: cross sectional study
Objective To describe the extent of late adverse event reporting by manufacturers to the US Food and Drug Administration’s (FDA) Manufacturer And User Facility Device Experience (MAUDE) database as well as the distribution of late reporting among manufacturers and associations with device characteristics. Design Cross sectional study. Setting The FDA MAUDE database, a central postmarket safety surveillance tool for US medical devices, from 1 September 2019 to 31 December 2022. Participants Medical device manufacturers that submitted initial adverse event reports to the FDA between 1 September 2019 and 31 December 2022. Main outcome measures Time in days between date manufacturer was notified of event and date of FDA receipt of adverse event reports, proportion of reports reported late (after the required 30 day window as required by FDA regulation), and distribution of late reporting among manufacturers and medical devices. Results 13 587 reports were of deaths, 1 552 268 of injuries, and 2 866 693 of malfunctions received by the FDA from 3028 unique manufacturers and 88 448 unique medical devices in the three and a half year period. Of 4 432 548 included reports, 71.0% (n=3 146 957) of adverse events were reported within 30 days (on time), 4.5% (n=197 606) were reported between 31 and 180 days (late), and 9.1% (n=402 891) were after 180 days (late). 15.5% of reports (n=685 094) had missing or invalid date data provided by the manufacturer. Three manufactures and 13 medical devices were attributed to 54.8% of late reports. Conclusions Nearly a third of manufacturer reports of medical device adverse events were not demonstrably submitted to the FDA within the regulatory deadline, with most late reports being submitted more than six months after manufacturer notification. Most late reports were submitted by a small number of manufacturers. Late adverse event reporting may prevent early detection of patient safety concerns.